National and Kapodistrian University of Athens
Οι μεταβολές του σωματοτρόπου άξονα GH/IGF-1 στη νοσογόνο παχυσαρκία μετά από βαριατρική χειρουργική επέμβαση
Abstract
dc:descriptionThe manuscript addresses the variation of somatotropic axis (GH/IGF-1) and its impact in anthropometric parameters and lipid metabolism of morbidly obese nondiabetic patients. In morbidly obese patients the frequency and the amplitude of growth hormone (GH) secretion is markedly suppressed followed by the reduction of Insulin-like growth factor-1(IGF-1)’s production. The mechanisms of this suppression are not well known. The main factor of this suppression is considered the negative feedback that visceral adiposity and high free fatty acids(FFA) levels exert to pituitary gland. It has been supported that the suppression of somatotropic axis could further burden and maintain obesity status. The suppression of somatotropic axis is considered responsible also for the altered lipid metabolism in these patients. We support that after bariatric surgery, the weight loss obtained can ameliorate somatotropic axis function and subsequently lipid metabolism in these group of patients. In the present study we analyzed somatotropic axis variations after two newly evolved bariatric surgeries, LSG(laparoscopic Sleeve Gastrectomy) and LOAGB(laparoscopic One Anastomosis Gastric Bypass) performed to 123 morbidly obese nondiabetic patients. We also analyzed anthropometric (BMI, Waist and Hip circumference) and metabolic parameters such as total Cholesterol, LDL, HDL, Triglycerides levels as well as their precursor molecules ApolipoproteinB, ApolipoproteinA1, VLDL and Lipoprotein(a) for which none therapeutic approach have been able to efficiently control it until now. We have obtained the correlations between somatotropic axis and anthropometric and lipid variations 1,6 and 12 months postoperatively.GH has increased significantly after surgery and particularly after LOAGB this increase was significantly correlated with the reduction of the more atherogenic lipoprotein such as ApoB and Lp(a). All anthropometric parameters were reduced and cardioprotective lipoproteins such as HDL and its precursor molecule ApoA1 were significantly increased. We concluded that LSG and LOAGB could be proposed as another effective treatment in morbidly obese nondiabetic patients as the beneficial actions of weight loss in relation to the increase in GH levels ameliorates their metabolic profile and reduces cardiovascular risk factors.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Barmpari, Maria
- Μπαρμπαρή, Μαρία
Subjects
dc:subject × 14- Παχυσαρκία, νοσογόνος
- Αυξητική ορμόνη
- Βαριατρική χειρουργική
- Λιπίδια
- Ινσουλινοειδής αυξητικός παράγοντας-1 (IGF-1)
- Growth hormone (GH)
- Morbid obesity
- Lipid metabolism
- Bariatric surgery
- Insulin like growth factor-1 (IGF-1
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46794